0001209191-20-007057.txt : 20200205 0001209191-20-007057.hdr.sgml : 20200205 20200205201930 ACCESSION NUMBER: 0001209191-20-007057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200204 FILED AS OF DATE: 20200205 DATE AS OF CHANGE: 20200205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Belsky Marc CENTRAL INDEX KEY: 0001382629 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 20580550 MAIL ADDRESS: STREET 1: FIVE PRIME THERAPEUTICS STREET 2: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-04 0 0001645666 Kezar Life Sciences, Inc. KZR 0001382629 Belsky Marc C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 CFO Common Stock 2020-02-04 4 P 0 15384 2.60 A 15384 D Common Stock 2000 I By Trust Shares were purchased in a public offering of the Issuer at a public offering price of $2.60. /s/ Marc Belsky 2020-02-05